Designing lenalidomide cocrystals with an extended-release profile for improved pulmonary drug delivery
This work describes a lenalidomide–melamine cocrystal with a lower solubility than pure lenalidomide, making it suitable for inhalable formulations.
Authors
- Mark R. Wilson (ORCID: https://orcid.org/0000-0001-6413-2780)
- James F. McCabe (ORCID: https://orcid.org/0000-0002-6062-2253)
- Gary Tomkinson
- Clare S. Mahon (ORCID: https://orcid.org/0000-0002-7358-1497)
- Sean Askin (ORCID: https://orcid.org/0000-0002-2643-3192)
- Jonathan W. Steed (ORCID: https://orcid.org/0000-0002-7466-7794)
- Martin A. Screen
Institutions
- AstraZeneca (United Kingdom) (GB)
- Durham University (GB)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Poland) (PL)
Publication Details
- Journal
- New Journal of Chemistry
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5nj00425j
- Citations
- 3
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 4.51
Funders
- AstraZeneca
- Durham University
- Engineering and Physical Sciences Research Council